Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Immunai’s end-to-end single-cell platform enables high resolution profiling of the immune system at industrial scale, generating biological insights that accelerate R&D and power novel discoveries
B2C, B2B
26 to 50
Seed
$20,000,000
Launched
2019
Healthcare
Health Care Facilities & Hospitals
Biotechnology
Decoding the Immune System to Improve Health
N/A
Analytics
Service
Yes
Active
Machine Learning
Machine Perception
Natural Language Processing
N/A
Software
3
1
$215M
Company was founded 2019 and it took almost 2 years (Oct 2021) to raise first external round
Interested in researching Immunai?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Immunai
Interested in what they do or partnership?
Learn more about how they work